Heterocyclic Compounds

Matches 1 - 50 out of 15,415	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/088237A1	LUMINESCENT MATERIAL, USE THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
WO/2024/090775A1	HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING ELEMENT The present specification provides a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer of an organic light-emitting device.
WO/2024/091983A1	THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION The present invention relates to novel compounds and compositions thereof. The compositions are useful in the treatment of an epithelial or endothelial barrier dysfunction disorder in a subject.
WO/2024/091538A1	COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
WO/2024/089023A1	PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
WO/2024/087977A1	PHENYLUREA COMPOUND, AND PREPARATION METHOD THEREFOR, USE THEREOF AND PHARMACEUTICAL COMPOSITION THEREOF The present invention relates to a phenylurea compound capable of targeting SHP2, and a preparation method therefor, the use thereof and a pharmaceutical composition thereof. The compound is as represented by formula (I). The present inv...
WO/2024/085699A1	COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF The present disclosure provides a compound of a specific chemical structure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, which has excellent activity in te...
WO/2024/083773A1	TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS The present invention relates to compounds, compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythemato...
WO/2024/086644A1	CEREBLON LIGANDS AND USES THEREOF Described herein are compounds or conjugates of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain pr...
WO/2024/086111A1	ANTI-VIRAL COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2024/086634A1	HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...
WO/2024/083237A1	SUBSTITUTED HETEROARYL BICYCLIC COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF The disclosure provides substituted heteroaryl bicyclic compounds as represented in Formula I and the use thereof, wherein, A1, A2, B1, B2, B3, ring Z, L, Cy1 and Cy2 are defined herein. The compounds of Formula I can be used to prevent ...
WO/2024/086744A2	COMPOSITIONS AND USES THEREOF Provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Formula (I) are as defined in the application. Such compounds can be useful as anti-cancer agents.
WO/2024/081372A1	PROCESSES FOR THE PREPARATION OF THE AGENT-LINKER CONJUGATE CL2A-SN-38 AND THE IMMUNOCONJUGATES SACITUZUMAB GOVITECAN AND LABETUZUMAB GOVETICAN The present invention relates to processes for the preparation of the compound of formula 1 from the intermediates the intermediates of formulae 8 to 10 in the presence of the cyclisation catalyst CuSO4 Compound 1 is the agent-linker con...
WO/2024/078569A1	AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF The present invention relates to an aromatic amide derivative, a preparation method therefor, and a use of a pharmaceutical composition comprising same in medicine. Specifically, the present invention relates to an aromatic amide derivat...
WO/2024/081318A1	ANTI-VIRAL COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2024/081904A1	METHODS FOR TREATING CANCER This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
WO/2024/081927A1	COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
WO/2024/078649A1	SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE The invention relates to furopyridine compounds of formula (I) for use in the treatment of FLT3-related, DDR-related and MAP4K-related diseases.
WO/2024/078592A1	DRUG TARGETING FIBROBLAST ACTIVATION PROTEIN AND USE THEREOF The present invention relates to a compound targeting fibroblast activation protein (FAP) as shown in formula (X) and a use thereof, and further relates to a pharmaceutical composition containing the compound and a use. The compound or t...
WO/2024/078449A1	COMPOUNDS, COMPOSITIONS AND METHODS The present disclosure relates to anticancer compounds, including, but not limited to, antibody-drug conjugates using the same, which compounds and ACDs thereof are suitable for the treatment of cancer.
WO/2024/074611A1	PRMT5 INHIBITORS The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
WO/2024/077006A1	FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
WO/2024/075051A1	HSD17B13 INHIBITORS AND/OR DEGRADERS Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD an...
WO/2024/075070A2	NOVEL BICYCLIC HETEROCYCLYL COMPOUNDS AND USE THEREOF The present invention relates to a compound represented by chemical formula 1 as an SOS1 inhibitor, optical isomers thereof, stereoisomers thereof, solvates thereof, isotopic variants thereof, tautomers thereof, or pharmaceutically accep...
WO/2024/073475A1	CEREBLON LIGANDS AND USES THEREOF Described herein are compounds of Formula II or conjugates of Formula II' and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or degraders for certain p...
WO/2024/066984A1	TRICYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE Provided in the present invention is a tricyclic derivative, and the structure thereof is as shown in formula (I). In addition, further disclosed in the present invention are a pharmaceutically acceptable salt of the derivative, a stereo...
WO/2024/067445A1	NOVEL PRMT5 INHIBITOR AND USE THEREOF Provided are a compound of formula (I) having inhibitory activity for protein arginine methyltransferase 5, and a method for synthesis and use of the compound.
WO/2024/073587A1	N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF Compounds and methods for inhibiting Nrf2 by activating KEAP1.
WO/2024/069634A1	MICROTUBULE TARGETING AGENTS The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of cancer in a subject in need thereof are also provided.
WO/2024/067811A1	LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF Provided herein are compounds having formulas (I) or (VII) or pharmaceutically acceptable salts, tautomers, isotopologues, stereoisomers, or prodrugs thereof; ligand-drug conjugates and pharmaceutically acceptable salts or solvates there...
WO/2024/073426A1	1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
WO/2024/068517A1	3-(HETERO)ARYL-5-CHLORODIFLUOROMETHYL-1,2,4-OXADIAZOLE AS FUNGICIDE The present invention relates to 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
WO/2024/069592A1	N-(5-SUBSTITUTED-[(L,3,4-THIADIAZOLYL) OR (L,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The application further discloses the use of a com...
WO/2024/069448A1	SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME The present disclosure includes substituted 1-arylaminocarbonyl-1'-heteroaryl compounds, substituted 1-heteroarylaminocarbonyl-1'-heteroaryl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds...
WO/2024/062997A1	COMPOUND, ORGANIC THIN FILM, AND PHOTOELECTRIC CONVERSION ELEMENT Compounds represented by the following general formula are useful as material for a photoelectric conversion element. Y is O or S, Ar1 and Ar2 are, e.g., aromatic hydrocarbon groups, and one of X1 to X4 is, e.g., a diarylamino group.
WO/2024/061048A1	CLASS OF LYCORINE DERIVATIVES, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF IN PREPARATION OF ANTIVIRAL DRUGS Disclosed are a class of lycorine derivatives represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The lycorine derivatives ...
WO/2024/061367A1	NOVEL COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Disclosed are a novel compound, a pharmaceutical composition thereof, and use thereof. The novel compound is represented by formula (I), wherein the details of the definition of each substituent group are shown in the specification. The ...
WO/2024/064316A1	COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 INHIBITORS AND USES THEREOF Described herein are compounds and conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 inhibitors or degraders).
WO/2024/063143A1	FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT The present invention relates to a compound represented by formula (I) or (II) or a pharmaceutically acceptable salt thereof.　Formula (I): [wherein: A1 is C(R1), etc.; R1 is a hydrogen atom, etc.; R8 is a hydrogen atom, etc.; B1 is CH,...
WO/2024/061357A1	HARRINGTONINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF The present invention relates to the field of pharmaceutical compounds, and relates to a harringtonine derivative, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The harringtonine derivative and t...
WO/2024/064823A2	COMPOSITIONS OF STAUROSPORINE ANALOGS AND USES THEREOF Provided herein, inter alia, are compositions comprising a staurosporine analog and methods for their use in cancer treatment.
WO/2024/064335A1	NAPHTHYL-SUBSTITUTED PYRANOPYRIMIDINONES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS The disclosure provides naphthyl-substituted pyranopyrimidinones and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras activity and their use in the treatment of medical disorders, such as cancer.
WO/2024/059317A1	YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS Provided are YAP/TAZ-TEAD oncoproteins inhibitors of Formula (I), or a stereoisomer, and/or a pharmaceutically acceptable salt, and/or solvate thereof, pharmaceutical compositions thereof, and methods of treatment.
WO/2024/059087A1	3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS Disclosed are compounds represented by formulae (I) and (II): or a pharmaceutically acceptable salt thereof. Compounds of formula (I) and (II) are useful for treating coronavirus infection via inhibition of the protease Mpro.
WO/2024/059249A1	M4 ACTIVATORS/MODULATORS AND USES THEREOF The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
WO/2024/059491A1	SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME The disclosure is directed to novel solid-state forms of Compound 9 and pharmaceutically acceptable salts of Compound 9, compositions comprising the same, and methods of using the same, including use in treating cancer, hypoxia related p...
WO/2024/059263A1	METHODS FOR PREPARING MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS The invention provides novel improved methods for preparing maytansinoid derivatives with self-immolative peptide linkers as well as their synthetic precursors.
WO/2024/059236A1	NOVEL CAMPTOTHECIN ANALOGS AND IMMUNOCONJUGATES THEREOF The invention provides novel camptothecin analogs and immunoconjugates thereof, as well as pharmaceutical compositions and methods of preparation and use for treating various diseases and disorders (e.g., cancer).
WO/2024/059524A1	PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...

Matches 1 - 50 out of 15,415	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >